Señales en vivo de GLYC | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Stats
Volumen de hoy	1.15M
Volumen promedio	508 379
Capitalización de mercado	117.94M
EPS	$0 ( 2024-05-01 )
Próxima fecha de ganancias	( $-0.150 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.16
ATR14	$0.00700 (0.38%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Koenig Scott	Buy	40 000	Stock Option (right to buy)
2024-05-01	Goldberg Mark Alan	Buy	40 000	Stock Option (right to buy)
2024-05-01	Pearson Timothy R	Buy	40 000	Stock Option (right to buy)
2024-05-01	King Rachel K.	Buy	40 000	Stock Option (right to buy)
2024-05-01	Andrews Patricia S	Buy	40 000	Stock Option (right to buy)

INSIDER POWER
29.99
Last 98 transactions
Buy: 6 982 849 \| Sell: 4 750 194

Volumen Correlación

Largo: 0.19 (neutral)

Corto: -0.28 (neutral)

Signal:(76.115) Neutral

GlycoMimetics Inc Correlación

10 Correlaciones Más Positivas
LSXMA	0.92
LSXMK	0.917
FRST	0.889
ESGRO	0.88
FSFG	0.868
BIB	0.864
CERC	0.856
AUTL	0.855
IMCR	0.853
BBH	0.845

10 Correlaciones Más Negativas
RMRM	-0.952
VERU	-0.871
IZEA	-0.837
BIS	-0.83
ACRX	-0.812

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

GlycoMimetics Inc Correlación - Moneda/Commodity

-0.25
( neutral )

0.03
( neutral )

0.00
( neutral )

-0.46
( neutral )

0.84
( strong )

GlycoMimetics Inc Finanzas

Annual	2023
Ingresos:	$10 000.00
Beneficio Bruto:	$-143 301 (-1 433.01 %)
EPS:	$-0.580

FY	2023
Ingresos:	$10 000.00
Beneficio Bruto:	$-143 301 (-1 433.01 %)
EPS:	$-0.580

FY	2022
Ingresos:	$74 925.00
Beneficio Bruto:	$-957 231 (-1 277.59 %)
EPS:	$-1.780

FY	2021
Ingresos:	$1 160.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.230

Financial Reports:

No articles found.

GlycoMimetics Inc

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Actualizaciones en tiempo real para GlycoMimetics Inc [GLYC]

Upcoming Earnings Alert